Y-Intercept (HK)’s bluebird bio BLUE Stock Holding History

Y-Intercept (HK)’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,438	Closed	-$148K	–	1244
2023 Q3	$148K	Buy	+2,438	New	+$171K	0.01%	934

Other funds holding BLUE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

GCM

Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Y-Intercept (HK)'s BLUE Position: Q4 2023 in Review

Y-Intercept (HK) sold out of bluebird bio (BLUE) in Q4 2023, closing a stake of 2,438 shares — an estimated $148K sold.

Y-Intercept (HK) first reported a position in BLUE in Q3 2023 and held it in 1 quarter. The position peaked at $148K in Q3 2023. 187 funds tracked by Wall St. Rank hold BLUE as of Q4 2023.

Y-Intercept (HK) reported no remaining bluebird bio position as of Q4 2023 after selling out during the quarter.
Y-Intercept (HK) sold 2,438 bluebird bio shares in Q4 2023, an estimated $148K.
Y-Intercept (HK) first reported a position in bluebird bio in Q3 2023 and held it in 1 quarter.
Y-Intercept (HK)'s bluebird bio position peaked at $148K in Q3 2023.
187 funds tracked by Wall St. Rank held bluebird bio as of Q4 2023.

Based on Y-Intercept (HK)'s 13F filing for Q4 2023, filed 13 Feb 2024.